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Our study demonstrates that epidermal Langerhans cells 
(LC) of healthy human skin produce Transforming growth 
factor-fJ (TGF-fJ) . This multipotent mediator might keep the 
immunocompetent LC in an "immature" stage, in which 
they are able to capture and process antigen. Development to 
E pidermal Langerhans cells (LC) are potent antigen-pro-cessing and -presenting dendritic cells in human skin that are decisively involved in MHC class II-restricted cellular immune responses [1] . These bone-marrow-derived cells can be found in immature and mature stages 
[2,3]. Immature dendritic cells are weak stimulators of resting T 
lymphocytes, but are excellent in processing antigens. Depending 
on their state of maturation LC express different surface molecules 
such as MHC class II, CDl a, Fc-receptor II (CDw32), CD45, 
CD23 [4] , CD18, and CD56 [intercellular adhesion molecule 1 
(ICAM-l)] [3 - 5]. The functional and phenotypic characteristics of 
dendritic cells are markedly influenced by cytokines. Up to the 
present time, few data are available about the transcription and 
expression of cell medi.ators by this human skin cell subset. LC can 
produce tumor necrosis factor (TNF-a) and granulocyte 
macrophage - colony-stimulating factor (GM-CSF), whereas there 
is controversy regarding production of other cytokines like ,-inter-
feron (IFN), interleukin (IL)- l , and IL-6 [2]. No data are available 
about the multifunctional mediator "transforming growth factor 
type beta" (TGF-P) [6] . 
T hree distinct homodimeric TGF-p molecules, TGF-pl, TGF-
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Abbreviations: 
AEC: aminoethylcarbazole 
AP: alkaline phosphatase 
APAAP: alkaline phosphatase anti- alkaline phosphatase 
FCS: fetal ca lf serum 
FITC: fluorescein isothiocyanate 
GM-CSF: granulocyte macrophage -colony-stimulating factor 
IFN: interferon 
IIF: indirect immunofluorescence 
IL: interleukin 
LC: epidermal Langerhans cell 
MEM: modified Eagle'S medium 
MHC: major histocompatibility complex 
MoAB: monoclonal antibody 
PBS: phosphate-buffered saline 
POD: peroxidase 
TG F: transforming growth factor 
T NF: tumor necrosis factor 
TRITC: tetramethyl rhodamin isothiocyanate 
potent antigen-presenting cells would become possible after 
migration from the epidermal network to the draining 
lymph node to stimulate (auto-)reactive T-cell clones.] Invest 
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P2, and TGF-p3, as well as heterodimeric combinations of the sub-
units, have been identified and their actions depend on cell type, 
tissue localization, and the presence of other cytokines [6]. Binding 
ofTGF-pl or TGF-p2 to a 280-kD protein receptor [6] results in an 
inhibition of epithelial cell proliferation and influences cell-differ-
entiation mechanisms [7,8]. 
Most of the cell types that respond to the TGF-p and the great 
variety of cellular responses elicited by these factors have been stud-
ied by using in vitro systems, in which both TGF-pl and TGF-/f?-
were shown to inhibit strongly the proliferation and DNA syntheSIS 
of normal and certain tumor-derived epithelial cell lines [8,9]. ThIS 
naturally occurring immunosuppressant has been found to interfere 
with certain accessory cell functions that are important in antigen 
presentation [10] . . 
TGF-p are present at relatively high levels in centers of actiVe 
tissue differentiation including cartilage, bone, thymus, bone 
marrow, hematopoietic stem cells in fetal liver , and activated mollO-
nuclear skin infiltrating cells [11 ] and in blood platelets, but the 
level of expression in normal epidermis was generally low [12]. f 
TGF-a and TGF-p possess opposing effects on proliferation a 
human prokeratinocytes. Whereas type-p arrests exponentially 
growing neonatal prokeratinocytes in the G 1 phase of the cell cycle 
in a reversible way, TGF-a stimulates colony growth [13]. . 
Because of the multifunctional roles ofTGF-p in the regulatIOn 
of many epithelial and epidermal cell functions and immune mech3i 
nisms, it is of special interest whether immunocompetent epiderJl1a 
LC would produce this mediator. 
MATERIALS AND METHODS 
Skin Specimens, LC Preparation, and Indirect Immun~f1uof 
rescence To avoid in vitro artefacts we studied the expreSSIon 0_ 
TGF-p in situ on frozen sections. Frozen 4-.wn vertical and tangen 
tial skin sections from dermatologically healthy skin were investI-
gated using indirect immunofluorescence (IIF) [14] . Briefly, in slni 
gle-staining IIF-tests, specimens were absorbed by either norma 
rabbit serum (10% in PBS, 15 min) or normal human AB and nt 
mal swine serum (10% in PBS, 15 min) . Then anti-CD1a monoc a 
nal antibodies (MoAB) (OKT6, Ortho Diagnostics Systems Inc~ 
Raritan, N]; 1 ,ug/ml in PBS, pH 7.2) or affinity chromatographY _ 
purified rabbit anti-porcine platel et TGF-pl antiserum (R&D Sy;) 
terns Inc., code] 897, MlI1neapoils, MN; 10 ,ug/ml ll1 PBS, pH 7. _ 
were incubated for 30 min at room temperature, detected by a fluO_ 
rescein isothiocyanate (FITC)-rabbit anti-mouse Ig conjugate (D;g 
kopatts, code F261, diluted 1 : 64) or by a FITC-swine anti-rabbit . II 
conjugate (Dakopatts, code F205, diluted 1 : 64 = 20 ,ug/ml proteI 
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~igure 1.. Immunofluorescence double staining in healthy human skin: 
Ola+ epidermal dendritic cells detected by TRITC-conjugate (A) double 
~alned with anti - TGF-fJ and FITC-conjugate (B) . Some double-positive 
I C are marked by arrows of the same size (original magnification X 250). 
'~fit I.·COla (C)/TGF-fJ (D) double-positive epidermal LC (original mag-
lll.lation X 500). Illset II: Immunohistochemical double staining (E) of an 
~r ermal dendritic cell in a tangential section using anti-COla (AP, Fast 
ueb bl~e color) and anti-TGF-fJ (POD, diaminobenzidine, brown color) anti odles (original magnification X 600). 
roncentration), respectively. Additionally, epidermal cells were 
reshly Isolated from healthy human skin (about 2% were identified 
as LS; by CD1a immunoreactivity) or cultured in modified Eagle's redlUm (MEM) with 10% fetal calf serum (FCS) in culture flasks 
Or 3 d as previously described [3] . 
Double Staining In double-staining experiments, sections and 
cytOSPl11 preparations were preabsorbed by normal human antibody, 
~~rn~1 goat, and normal swine serum (20% in PBS) and incubated 
TRtl11, room temperature) with anti-CDla MoAb followed by a 
I TC-conjugated goat anti-mouse IgG F(ab'h [1: 20 in ph os-
~ la~e-buffered saline (PBS), pre-absorbed with 10% normal human 
a~\ .ody serum, Cappel Lab., Cochranville, PA, code 7277 A] or 
(Da l11e phosphatase (AP)-conjugated goat anti-mouse IgG F(ab'h 
s lanava, Hamburg, Germany, code 115-056-044), Subsequently, 
b~~c~rnens were incubated with anti-porcine TGF-p polyclonal rab-
m ntlbody (pre-absorbed with 10% normal human, goat, and 
(Do~se serum) detected by FITC- or peroxidase (POD)-conjugated 
sorbe~pa~ts, code P399) swine anti-rabbit immunoglobulin (pre-ab-
oh' with 10% normal human, goat, and mouse serum). Immun-
zotst(ochernical stainings were developed with aminoethylcarba-
e ABC) for peroxidase and with Fast blue for AP as substrates. 
Control St " C . I d d' . I stai . alnlngs ross reactions were exc u e 111 S111g e-
usi nlng experiments by pre-absorption of specimens or by stainings 
ciftt ?nly fluorochrome-labeled conjugates. To exclude an unspe-
staiC . l11dl11g of the FITC-conjugate via Fc-receptors on LC control 
rab~lt~gs were performed a) omitting primary antibodies, b) using 
082) ntl- factor VIII - related antigen (10 Jlg/ml, Dakopatts, code 
werk and rabbit anti - factor XIII subunit A (Clotimmun, Behring-
FIT~' Marburg, Germany, 5 Jlg/ml) subsequently incubated with 
we u -~Ol1Jugated swine anti-rabbit (20 Jlg/ml). As positive control, 
crou sl TG~-P-producing cells of Glioblastoma cell line 308 (gen-
and ~y provided by A. Fontana, Section of Clinical Immunology 
land) [~~artment of Neurosurgery, University of Zurich, Switzer-
TGF_jJ ]. ~pccdiClty ofTGF-p staining was shown by inhibition of 
prOtc' ~ltlbody by preincubation with a fiftyfold excess ofTGF-p 
show
1
\ rom glioblastoma cell line 308 supernatants (previously 
n y Western blot analysis). 
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Figure 2. Control staining of healthy human skin with anti- factor VIII-
related antigen (A) and anti-factor XIIIa (B) detected with FITC-swine 
anti-rabbit conjugate. Absent immunostaining in the epidermis (original 
magnification X 250). 
RESULTS 
We found strong dendritic epidermal staining using anti - TG F-P 
antibody (Fig 1 b,d), which was absent after preincubation with 
TGF-p protein. The same immunohistologic procedure using anti-
bodies against factor VIII-related antigen (Fig 2a) and factor XIIIa 
(Fig 2b) revealed no intraepidermal staining. Double-staining pro-
cedures demonstrated these dendritic cells to be CDla/TGF-p dou-
ble positive (Fig la-d). This staining pattern was observed on all 
CD1a+ epidermal dendritic cells in vertical as well as tangential 
skin sections (Fig Ib,d). An only slight cytoplasmic as well as mem-
braneous staining pattern was seen on keratinocytes (not seen in 
figures demonstrated). 
In freshly isolated epidermal cell preparations we observed strong 
TGF-p expression on CDla positive cells besides faint staining of 
about 60 - 80% keratinocytes (Fig 3). In-contrast, cultured LC exhib-
ited a quantitatively and qualitatively reduced staining with anti-
TGF-p antibodies (figure not shown). 
Figure 3. Strong expression ofTGF-fJ (B; FITe) on COla-positive LC (A; 
TRITe) in freshly isolated epidermal cell preparation of healthy skin. Faint 
TGF-fJ staining of about 60-80% keratinocytes (B) (original magnification 
X600). 
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DISCUSSION 
Our data suggest an expression ofTGF-fi protein by human epider-
mal LC. Though we do not know whether the latent, biologically 
inactive TGF-fi precursor complex becomes activated in the normal 
human epidermis, TGF-fi might play an important role in the regu-
lation of cellular immune responses and/or in the differentiation 
and development of epidermal Langerhans cells in human skin. 
Recently, it was shown that only fresh isolated LC, the in vitro 
equivalent of intraepidermal LC, are resistant to the inhibition of 
antigen processing by TGF-fi, whereas cultured LC were not resist-
ant [10]. In healthy skin TGF-fi might possibly keep epidermal LC 
in an immature stage via autocrine and/or paracrine control mecha-
nisms. This would ensure that they can capture and process anti-
gens, but would suppress antigen presentation. Maturation to potent 
antigen-presenting cells would become possible after migration 
from the epidermal network to the draining lymph node as shown 
in cultured LC, the in vitro model for mature LC [3]. Furthermore, 
TGF-fi antagonizes IL-I - dependent T -lymphocyte proliferation 
[16] and possibly exerts profound immunosuppressive effect on lym-
phocyte function in healthy human skin. Recently, it was shown 
that human epidermal LC express integrins of the fil-subfamily 
[17].Though up to the present time functional data on LC are not 
available, this observation is of special interest because it could be 
shown that TGF-fi1 leads to a concomitant expression of 0'1-4 and 
fil integrin chains in W138 lung fibroblasts [18]. 
These first data about TGF-fi expression on human epidermal LC 
might provide a rational basis for further functional and molecular 
biologic studies on this multipotent mediator. 
We thallk DR. N. Romal/i, Department of Dermatology, Ulliversity oJIllllsbruck, 
Austria, Jor providing cytospih preparations oj LC and Jor critical reading oj the 
mal1uscript. 
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